MaxCyte, Inc. (MXCT)

MaxCyte's stock has been impacted by several key events over the past six months. On May 7, 2025, the stock experienced an 11.31% decline after reporting its first-quarter 2025 financial results. On August 6, 2025, the stock dropped 0.97% after announcing its second-quarter 2025 results, which included a revenue decline and lowered guidance. On November 12, 2025, the stock initially dropped 8.7% after reporting its third-quarter 2025 earnings, missing forecasts. In the third quarter of 2025, MaxCyte announced an operational restructuring. In October 2025, MaxCyte signed a new SPL agreement with Moonlight Bio. The stock has seen a significant decline of over 50% in the past year, but has shown a recent increase of 2.94% in the last week and 7.36% in the last month as of November 26, 2025.

The demand for MaxCyte's products and services is primarily driven by broader industry trends within the rapidly growing non-viral cell therapy market and advancements in regulatory approvals. The underlying demand is more closely tied to the development cycles of cell and gene therapies rather than traditional consumer seasonal patterns. Historically, there may be some seasonality in stock performance.

MaxCyte, Inc. is a biotechnology company specializing in cell engineering and therapeutic development, focusing on cell and gene therapy. Its core business revolves around its Flow Electroporation® technology, which enables high-performance cell engineering. The company's major products include the ExPERT™ platform, a suite of instruments and disposables designed for cell engineering. MaxCyte generates revenue through licensing agreements, partnerships, and the sale of disposable processing assemblies. In January 2025, MaxCyte acquired SeQure Dx, adding gene-editing safety and risk assessment services.

MaxCyte's headquarters are located in Gaithersburg/Rockville, Maryland, in the United States. The company's ExPERT platform is available worldwide, and MaxCyte is actively working to increase its presence in global markets, with a particular focus on Asia and Europe.

MaxCyte has maintained a strong brand reputation as a leader in the biotechnology sector and cell engineering. Its Flow Electroporation® technology is recognized for enabling the development of next-generation cell-based therapies. The support of CASEGEVY, the first non-viral engineered cell therapy product approved by the FDA, developed by its SPL client CRISPR Therapeutics and Vertex Pharmaceuticals, was a significant highlight. The acquisition of SeQure Dx in January 2025 further enhanced its reputation. No specific events negatively affecting MaxCyte's brand reputation were identified in the past year, although the company has faced financial performance challenges.

MaxCyte, Inc. has a substantial institutional ownership base, with 254 institutional owners and shareholders holding a total of over 80 million shares. Major institutional owners include BlackRock, Inc., Cadian Capital Management, Lp, Mirabella Financial Services Llp, Morgan Stanley, Vanguard Group Inc, Vitruvian Partners LLP, Mudita Advisors LLP, AXA Investment Managers S.A., and Geode Capital Management, Llc.